Results 201 to 210 of about 17,756 (247)

CD123-CAR T Cells Manufactured in the Presence of Dasatinib Induce High Grade CRS and/or IEC-HS without Improving Efficacy in Pediatric Patients with Recurrent/Refractory Leukemia

Blood
Background We are conducting a Phase 1 clinical study to evaluate the safety and efficacy of escalating doses of autologous CD123-CAR T cells for pediatric patients with r/r CD123-positive AML or ALL.
Swati Naik, Madden Renee, A. Talleur, Rebecca Epperly, T. Lockey, Jennyfer Bran, Liqing Tian, Ying Li, D. Keerthi, Alexandra Boyd, Amanda Lipsitt, J. Rubnitz, J. Klco, Barry L. Shulkin, S. Schell, Polly Adams, Jeoungeun J. Park, J. Riberdy, N. Shang, J. Zoine, Raghu Shanmugam, C. Nevitt, Unmesha Thanekar, Jennifer Wallace, Elaine Harstead, S. Perry, Catherine Willis, J. Métais, Deanna M. Langfitt, Sheng Zhou, S. Akel, Caitlin C. Zebley, J. Crawford, Ben Youngblood, Paul G. Thomas, Frank Fazio, B. Triplett, S. Gottschalk, M. Velasquez   +38 more
semanticscholar   +1 more source

Tagraxofusp, a first‐in‐class CD123‐targeted agent: Five‐year postapproval comprehensive review of the literature

Cancer
Tagraxofusp is a first‐in‐class CD123‐directed conjugate of an amended diphtheria toxin platform and recombinant interleukin 3. Binding and subsequent internalization of the drug result in cell death via disruption of intracellular protein synthesis ...
W. Jen, Marina Y. Konopleva, Naveen Pemmaraju   +2 more
semanticscholar   +1 more source

Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study

Leukemia and Lymphoma
CD123 “expression” is common in hematological malignancies, including acute lymphoblastic leukemia (ALL). Flotetuzumab is a novel, investigational CD3/CD123 DART®.
I. Aldoss, Jianying Zhang, Marjorie Robbins, Joo Y. Song, M. A. Al Malki, Salman Otoukesh, Karamjeet S. Sandhu, Vaibhav Agrawal, A. Herrera, L. Popplewell, Lucy Y. Ghoda, A. Stein, Guido Marcucci, Stephen J. Forman, V. Pullarkat   +14 more
semanticscholar   +1 more source

Prognostic Significance of CD123 Expression in Acute Myeloid Leukemia Treated with Venetoclax and Hypomethylating Agents

Blood
Introduction Acute myeloid leukemia (AML) with overexpression of CD123 is hyperproliferative, resistant to cell death, and has worse prognosis and survival in patients treated with intensive chemotherapy [Testa et al. 2002, Blood].
Bruce C. Tiu, Christina Su, Emma C. St. Martin, Jean S. Oak, Tian Y. Zhang, G. Mannis   +5 more
semanticscholar   +1 more source

Development of a novel engineered antibody targeting human CD123

Analytical Biochemistry, 2016
Antibody engineering involves a range of custom modifications of immunoglobulins to improve their affinity, valency, and pharmacokinetics, ensuring a better target therapy achievement. A number of therapeutic antibodies have been used for cell surface receptor blockage, interfering with the ligand binding and inhibiting receptor-driven activation of ...
Mohammad Ali Shokrgozar, Majid Golkar
exaly   +3 more sources

CD123 (Interleukin 3 receptor a chain).

2001
CD 123 is the interleukin 3 receptor alpha chain and is expressed on different type of myloid hematopoietic ...
Moretti S., LANZA, Francesco, Dabusti M., Tieghi A., CAMPIONI, Diana, Dominici M., Castoldi GL   +6 more
openaire   +2 more sources

[Significance of CD123 in histiocytic necrotizing lymphadenitis].

Zhonghua bing li xue za zhi = Chinese journal of pathology, 2015
To investigate the mode of presentation, cytologic features of the plasmacytoid dendritic cells (pDC), and the expression of CD123 and its significance in Kikuchi's disease.CD123 expression was evaluated by EliVision immunohistochemical staining in formalin-fixed and paraffin-embedded tissues from 30 cases of Kikuchi's disease, 5 cases of T cell ...
Xuejing, Wei, Xiaoge, Zhou, Jianlan, Xie, Xiaodan, Zheng, Yuanyuan, Zheng   +4 more
openaire   +1 more source

Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)

Blood, 2022
D. Sallman, D. DeAngelo, Naveen Pemmaraju, S. Dinner, Saar I. Gill, R. Olin, E. Wang, M. Konopleva, E. Stark, A. Korngold, A. Haider, Kate Backhouse, Carolyn Figliola, D. Lee, M. Frattini, C. Brownstein, G. Roboz   +16 more
semanticscholar   +1 more source

The Nup98::Nsd1 fusion gene induces CD123 expression in 32D cells

International journal of hematology, 2023
K. Okamoto, T. Imamura, Seiji Tanaka, T. Urata, Hideki Yoshida, Norio Shiba, T. Iehara   +6 more
semanticscholar   +1 more source

CD123 to the rescue

Blood
Anisha Elizabeth, Jacob, Girish, Venkataraman   +1 more
openaire   +2 more sources